Ishares Msci Italy ETF vs Pfizer Inc — how do they compare? Ishares Msci Italy ETF trades at $56.34 (market cap $1.14B), while Pfizer Inc trades at $28.19 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 139.1× Ishares Msci Italy ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 53 Days and Pfizer Inc for 158 Days on average.
| EWI | PFE | |
|---|---|---|
Market Cap | $1.14B | $158.56B |
Volume | 2,377,947 | 44,138,282 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $29.02 |
52-Week Low | $50.31 | $23.67 |
Typical Hold Time | 53 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →